Metal chaperones: A holistic approach to the treatment of alzheimer's disease

Frontiers in Psychiatry

Volumn 3, Issue MAR, 2012, Pages

  Adlard, Paul Anthony ^a   Bush, Ashley Ian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Cohaperone; Metal; PBT2; Therapeutic

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); AMYLOID BETA PROTEIN[1-42]; CARRIER PROTEIN; DIMEBON; GLYCOGEN SYNTHASE KINASE 3; HOMOTAURINE; METALLOCHAPERONE; PBT 2; PLACEBO; PROTEIN CTR1; PROTEIN ZIP; SEMAGACESTAT; SYNAPTOPHYSIN; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENZYME PHOSPHORYLATION; EXECUTIVE FUNCTION; HUMAN; ION TRANSPORT; LOW DRUG DOSE; METAL METABOLISM; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SHORT SURVEY;

EID: 84866871342     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2012.00015     Document Type: Short Survey

References (38)

1. Adlard, P. A., Bica, L, White, A. R., Nurjono, M., Filiz, G., Crouch, P. J., Donnelly, P. S., Cappai, R., Finkelstein, D. I., and Bush, A. I. (2011). Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS ONE 6, el7669. doi:10.1371/jour-nal.pone.0017669
2. Adlard, P. A., and Bush, A. I. (2006). Metals and Alzheimer's disease. J. Akheimers Dis. 10, 145-163.
3. Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu,X., Smith, J. P., Perez, K., Laughton, K., Li, Q. X., Charman, S. A., Nicolazzo, J. A., Wilkins, S., Deleva, K., Lynch, T., Kok, G., Ritchie, C. W., Tanzi, R. E., Cappai, R., Masters, C. L., Barnham, K. J., and Bush, A. I. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55.
4. Adlard,P.A.,James,S.A.,Bush,A.I.,and Masters, C. L. (2009). Beta-amyloid as a molecular therapeutic target in Alzheimer's disease. Drugs Today 45, 293-304.
5. Adlard, P. A., Parncutt, J. M., Finkelstein, D. I., and Bush, A. I. (2010). Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J. Neurosci. 30, 1631-1636.
6. Ba, L. A., Doering, M., Burkholz, T., and Jacob, C. (2009). Metal trafficking: from maintaining the metal homeostasis to future drug design. Metallomics 1,292-311.
7. Bayer, T. A., Schafer, S., Simons, A., Kemmling, A., Kamer, T., Tepest, R., Eckert, A., Schiissel, K., Eikenberg, O., Sturchler-Pierrat, C, Abramowski, D., Staufenbiel, M., and Multhaup, G. (2003). Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc. Nail. Acad. Sci. U.S.A. 100, 14187-14192.
8. Biran, Y., Masters, C. L., Barnham, K. J., Bush, A. I., and Adlard, P. A. (2009). Pharmacotherapeutic targets in Alzheimer's disease. J. Cell. MolMed. 13,61-86.
9. Cole, T. B., Wenzel, H. J., Kafer, K. E., Schwartzkroin, P. A., and Palmiter, R. D. (1999). Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc. Natl. Acad. Sci. U.S.A. 96, 1716-1721.
10. Crouch, P. J., Sawa, M. S., Hung, L. W., Donnelly, P. S., Mot, A. I., Parker, S. J., Greenough, M. A., Volitakis, I., Adlard, P. A., Cherny, R. A., Masters, C. L., Bush, A. I., Barnham, K. J., and White, A. R. (2011). The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J. Neurochetn. 119,220-230.
11. Deshpande, A., Kawai, H., Metherate, R., Glabe, C. G., and Busciglio, J. (2009). A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. /. Neurosci 29,4004-4015.
12. Duce, J. A., Bush, A. I., and Adlard, P. A. (2011). Role of amyloid-b-metal interactions in Alzheimer's disease. Future Neurol. 6, 641-659.
13. Faux, N. G., Ritchie, C. W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., Ingelsson, M., Masters, C. L., Tanzi, R. E., Cummings, J. L., Herd, C. M., and Bush, A. I. (2010). PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J. Akheimers Dis. 20, 509-516.
14. Flinn, J. M., Hunter, D., Linkous, D. H., Lanzirotti, A., Smith, L. N., Brightwell, J., and Jones, B. F. (2005). Enhanced zinc consumption causes memory deficits and increased brain levels of zinc. Physiol. Behav. 83, 793-803.
15. Golde, T. E., Schneider, L. S., and Koo, E.H. (2011). Antiabeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69,203-213.
16. Hynd, M. R., Scott, H. L, and Dodd, P. R. (2004). Glutamate-mediatedexcitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 45, 583-595.
17. Karran, E., Mercken, M., and De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698-712.
18. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., Wilson, J., Ritchie, C. W, and PBT2-201-EURO Study Group. (2008). Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase Ha, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7, 779-786.
19. Lee, J. Y., Cole, T. B., Palmiter, R. D., Suh, S. W, and Koh, J. Y. (2002). Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. USA 99, 7705-7710.
20. Lei, P., Ayton, S., Bush, A. I., and Adlard, P. A. (2011). GSK-3 in neurodegenerative diseases. Int. J. Alzheimer's Dis. 2011,189246.
21. Li, L., Sengupta, A., Haque, N., Grundke-Iqbal, I., and Iqbal, K. (2004). Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBSLett. 566,261-269.
22. Linkous, D. H., Adlard, P. A., Wanschura, P. B., Conko, K. M., and Flinn, J. M. (2009). The effects of enhanced zinc on spatial memory and plaque formation in transgenic mice. /. Akheimers Dis. 18, 565-579.
23. Lleo, A., Greenberg, S. M., and Growdon, J. H. (2006). Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med. 57, 513-533.
24. Lutsenko, S., and Petris, M. J. (2003). Function and regulation of the mammalian copper-transporting ATPases: insights from biochemical and cell biological approaches. J. Membr. Biol. 191, 1-12.
25. Masters, C. L., and Beyreuther, K. (2006). Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 129, 2823-2839.
26. Nakashima, A. S., Oddo, S., Laferla, F. M., and Dyck, R. H. (2010). Experience-dependent regulation of vesicular zinc in male and female 3xTg-AD mice. Neurobiol Aging 31, 605-613.
27. Palmiter, R. D., Cole, T. B., Quaife, C. J., and Findley, S. D. (1996). ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc. Natl. Acad. Sci. U.S.A. 93, 14934-14939.
28. Parsons, C. G., Stoffler, A., and Danysz, W. (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 53, 699-723.
29. Phinney, A. L, Drisaldi, B., Schmidt, S. D., Lugowski, S., Coronado, V., Liang, Y, Home, P., Yang, J., Sekoulidis, J., Coomaraswamy, J., Chishti, M. A., Cox, D. W., Mathews, P. M., Nixon, R. A., Carlson, G. A., St George-Hyslop, P., and Westaway, D. (2003) In vivo reduction of amyloid-beta by a mutant copper transporter. Proc. Natl. Acad. Sci. U.S.A. 100,14193-14198.
30. Railey, A. M., Groeber, C. M., and Flinn, J. M. (2011). The effect of metals on spatial memory in a transgenic mouse model of Alzheimer's disease. J. Akheimers Dis. 24, 375-381.
31. Sandstead, H. H. (1995). Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am. J. Clin. Nutr. 61,621S-624S.
32. Sayre, L. M., Perry, G., and Smith, M. A. (1999). Redox metals and neurodegenerative disease. Curr. Opin. Chem. Biol. 3, 220-225.
33. Sinha, S., and Taly, A. B. (2008). Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap. J. Neurol. Sci. 264, 129-132.
34. Smith, D. G., Cappai, R., and Barnham, K. J. (2007). The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta 1768,1976-1990.
35. Sonkusare, S. K., Kaul, C. L., and Ramarao, P. (2005). Dementia of Alzheimer's disease and other neurodegenerative disorders - memantine, a new hope. Pharmacol Res. 51, 1-17.
36. Sperling, R. A., Jack, C. R. Jr., and Aisen, P. S. (2011). Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cml33.
37. Stoltenberg, M., Bush, A. I., Bach, G., Smidt, K., Larsen, A., Rungby J, Lund S, Doering P, Danscher G. (2007). Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 150, 357-369.
38. Tardiff, D. E, Tucci, M. L, Caldwell, K. A., Caldwell, G. A., and Lindquist, S. (2012). Different 8-hydroxyquinolines protect models of TDP-43, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J. Biol. Chem. 287,4107-4120.